Immunogenicity of induced pluripotent stem cells

  title={Immunogenicity of induced pluripotent stem cells},
  author={Tongbiao Zhao and Zhen-Ning Zhang and Zhili Rong and Yang Xu},
Induced pluripotent stem cells (iPSCs), reprogrammed from somatic cells with defined factors, hold great promise for regenerative medicine as the renewable source of autologous cells. Whereas it has been generally assumed that these autologous cells should be immune-tolerated by the recipient from whom the iPSCs are derived, their immunogenicity has not been vigorously examined. We show here that, whereas embryonic stem cells (ESCs) derived from inbred C57BL/6 (B6) mice can efficiently form… 

Cells derived from iPSC can be immunogenic — Yes or No?

Two studies support the conclusions that some certain but not all tissues derived from iPSCs can be immunogenic, although they claimed either “negligible” or “lack of” immunogenicity in iPSC derivatives.

Stem cells: iPS cells under attack

In experiments in which iPS cells were reprogrammed using a retroviral or non-integrative episomal approach and then transplanted into mice, teratoma cells derived from the i PS cells were rejected by the immune system, even in syngeneic recipients, suggesting that altered gene expression in some cells differentiated from iPS Cells can induce T-cell-dependent immune responses.

Brief Report: Immune Microenvironment Determines the Immunogenicity of Induced Pluripotent Stem Cell Derivatives

It is shown that the immune response toward antigens is dependent on the immune environment of the transplantation site, and the cotransplantation of mature B6 dendritic cells under the kidney capsule leads to immune rejection of B6 iPSC‐derived grafts but not B6 ESC‐ derived grafts.

Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells

Limited immunogenicity of transplanted cells differentiated from iPSCs and ES cells is suggested, suggesting limited immune responses in transplant recipients even when iPSC-derived differentiated cells are transplanted.

Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy

Current understanding of inherent immunogenicity of PSC lines, especially that of the human iPSC lines and their cellular derivatives, and strategies to overcome it are reviewed.

Immunogenicity of induced pluripotent stem cells.

A new study shows the immunogenicity of induced pluripotent stem cells by the direct transplantation of undifferentiated cells into syngenic mice, indicating that cells differentiated from iPSCs can at least partially replace the biological functions of various organs.

Natural Killer Cells Prevent the Formation of Teratomas Derived From Human Induced Pluripotent Stem Cells

The findings suggest that autologous hiPSC-derived therapies are unlikely to form teratomas in the presence of NK cells, and that established ter atomas were not targeted by NK cells and instead were efficiently rejected by allogeneic but not autOLOGous T cells in Hu-AT mice.

Low immunogenicity of mouse induced pluripotent stem cell-derived neural stem/progenitor cells

The immunogenicity and post-transplantation immunological dynamics of iPSC-NSPCs resemble those of fetus-N SPCs.

Immunogenicity and tumorigenicity of human pluripotent stem cells

iPSC- derived cells could be immunogenic in syngeneic recipients but immune tolerated due to immune suppressive microenvironment, and significant progress has been made to establish novel strategies to induce immune tolerance of allogeneic hESC-derived allografts.

Low Immunogenicity of Neural Progenitor Cells Differentiated from Induced Pluripotent Stem Cells Derived from Less Immunogenic Somatic Cells

The groundbreaking discovery of induced pluripotent stem cells (iPS cells) provides a new source for cell therapy. However, whether the iPS derived functional lineages from different cell origins



Generation of human induced pluripotent stem cells from dermal fibroblasts

Methods to use dermal fibroblasts easily obtained from an individual human to generate human induced pluripotent stem (iPS) cells by ectopic expression of the defined transcription factors KLF4, OCT4, SOX2, and C-MYC are described.

Induced Pluripotent Stem Cells Generated Without Viral Integration

This work generated mouse induced pluripotent stem cells from fibroblasts and liver cells by using nonintegrating adenoviruses transiently expressing Oct4, Sox2, Klf4, and c-Myc, providing strong evidence that insertional mutagenesis is not required for in vitro reprogramming.

Reprogramming of human somatic cells to pluripotency with defined factors

The data demonstrate that defined factors can reprogramme human cells to pluripotency, and establish a method whereby patient-specific cells might be established in culture.

Natural immunity to pluripotency antigen OCT4 in humans

It is shown that OCT4-specific T cells can be readily detected in freshly isolated T cells from most (>80%) healthy donors, and natural immunity to this antigen may allow immune-based targeting of pluripotency-related pathways for prevention of cancers, including those in the setting of ES/IPS-based therapies.

Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells

Somatic cell nuclear transfer allows trans-acting factors present in the mammalian oocyte to reprogram somatic cell nuclei to an undifferentiated state. We show that four factors (OCT4, SOX2, NANOG,

Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells

It is shown that iPSCs obtained from mouse fibroblasts, hematopoietic and myogenic cells exhibit distinct transcriptional and epigenetic patterns, and it is demonstrated that cellular origin influences the in vitro differentiation potentials of iPSC into embryoid bodies and different hematopsic cell types.

Epigenetic memory in induced pluripotent stem cells

It is observed that low-passage induced pluripotent stem cells (iPSCs) derived by factor-based reprogramming of adult murine tissues harbour residual DNA methylation signatures characteristic of their somatic tissue of origin, which favours their differentiation along lineages related to the donor cell, while restricting alternative cell fates.